Advanced Miniature In-Line Blood Gas Analyzer Launched in Europe
|
By LabMedica International staff writers Posted on 31 Mar 2015 |

Image: The miniature Proxima Sensor is integrated into a patient’s arterial line to be used for directly monitoring blood gases and electrolytes over a 72 hour period as many times as required (Photo courtesy of Sphere Medical).

Image: The new Proxima in-line patient-dedicated point-of-care blood gas analyzer incorporates Proxima Sensor (in foreground) and dedicated bedside monitor (Photo courtesy of Sphere Medical).
A CE-marked patient-dedicated system, presented at ISICEM 2015, delivers point-of-care testing (POCT) by enabling critical care staff to obtain rapid and frequent laboratory-accurate arterial blood gas measurements without leaving the patient’s bedside, facilitating effective and timely clinical decisions.
Sphere Medical (Cambridge, UK) presented its Proxima System at the 35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015; Brussels, Belgium, March 17-20, 2015) for launch in mainland Europe. Proxima revolutionizes conventional POCT as it is attached directly to the patient through their arterial line. The miniature Proxima Sensor, containing a range of biological sensors, sits in series in the arterial line with the blood pressure transducer. For the first time, blood gas results can be delivered, like blood pressure results, within the patient’s bed space.
Proxima is simple to use, enables closed blood sampling, and is operated via the touch-screen interface of its dedicated bedside monitor. Blood is withdrawn from the patient directly into the Proxima Sensor and a panel of analytes is measured. All blood is returned to the patient – promoting blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. The disposable sensor can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required.
Proxima has been fully evaluated and validated in a clinical setting. A recent observational method comparison study at Queen Elizabeth Hospital (Birmingham, UK) showed excellent agreement between Proxima and hospital standard benchtop blood gas analyzers, measuring various parameters of intensive care unit (ICU) patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery, and sepsis.
Dr. Tom Clutton-Brock, senior lecturer, Anaesthesia and Intensive Care Medicine, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in-patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” At ISICEM 2015 Dr. Clutton-Brock presented on “Bedside Blood Analysis,” discussing how frequent measurement of arterial blood samples is a key component in the effective management of critical care patients, particularly those who are unstable. At a poster session, Dr. Clutton-Brock and Dr. Jess Fox (Sphere Medical) discussed the excellent evaluation results of the Queen Elizabeth Hospital study.
Related Links:
Sphere Medical
35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015)
Sphere Medical (Cambridge, UK) presented its Proxima System at the 35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015; Brussels, Belgium, March 17-20, 2015) for launch in mainland Europe. Proxima revolutionizes conventional POCT as it is attached directly to the patient through their arterial line. The miniature Proxima Sensor, containing a range of biological sensors, sits in series in the arterial line with the blood pressure transducer. For the first time, blood gas results can be delivered, like blood pressure results, within the patient’s bed space.
Proxima is simple to use, enables closed blood sampling, and is operated via the touch-screen interface of its dedicated bedside monitor. Blood is withdrawn from the patient directly into the Proxima Sensor and a panel of analytes is measured. All blood is returned to the patient – promoting blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. The disposable sensor can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required.
Proxima has been fully evaluated and validated in a clinical setting. A recent observational method comparison study at Queen Elizabeth Hospital (Birmingham, UK) showed excellent agreement between Proxima and hospital standard benchtop blood gas analyzers, measuring various parameters of intensive care unit (ICU) patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery, and sepsis.
Dr. Tom Clutton-Brock, senior lecturer, Anaesthesia and Intensive Care Medicine, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in-patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” At ISICEM 2015 Dr. Clutton-Brock presented on “Bedside Blood Analysis,” discussing how frequent measurement of arterial blood samples is a key component in the effective management of critical care patients, particularly those who are unstable. At a poster session, Dr. Clutton-Brock and Dr. Jess Fox (Sphere Medical) discussed the excellent evaluation results of the Queen Elizabeth Hospital study.
Related Links:
Sphere Medical
35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015)
Latest Hematology News
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
Channels
Molecular Diagnostics
view channel
Genetic Testing Identifies High-Risk Patients with Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is a lifelong, unpredictable condition that can require advanced therapies or surgery. More than half a million people in the U.... Read more
Ancestry-Informed Genomics Advances Precision Cancer Prognosis
Predicting survival in common cancers remains imprecise despite widespread use of tumor sequencing to guide care. Outcome disparities among patient populations also persist, and the genomic drivers behind... Read more
New Blood Test Predicts Organ-Specific Disease and Mortality Years in Advance
Quantifying organ-specific aging remains a diagnostic challenge, even as age-related disorders drive morbidity and mortality worldwide. Chronological age poorly reflects the physiologic decline that predisposes... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more








